68858-20-8 Fmoc-L-Val-OH

68858-20-8 Fmoc-L-Val-OH is one of Abaloparatide intermediates.

First of all, Abaloparatide acts to regulate metabolism and promote bone formation by selectively activating the signaling channel of PTH1 type 1 receptor (PTH1R). It significantly increases bone density and reduces the risk of fractures. Studies have shown that in men with osteoporosis, treatment with Abaloparatide significantly and rapidly improves BMD (bone mineral density) of the spine, femoral neck, and total hip compared to placebo.

Second, Abaloparatide has been approved for marketing by the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women who are at risk of fracture or who have not responded to other therapeutic agents. In addition, the drug is also indicated for adult men for whom testosterone replacement therapy is not indicated to reduce the patient's risk of vertebral fractures and to increase bone strength in hip and non-hip fractures.

When using Abaloparatide, the recommended dosage is 80mcg administered subcutaneously once daily. If the patient's dietary intake is inadequate, calcium and vitamin D should be supplemented.Before administering, make sure that the drug syringe and needle are clean and sterile.

Overall, Abaloparatide has been shown to be effective in the treatment of osteoporosis and has been widely used in clinical practice.